Ftse Mib
37.977,74
0,18%
DAX
22.490,09
-0,54%
S&P 500
6.122,80
0,13%
NASDAQ
19.969,62
0,12%
Bitcoin
97.015,14
0,42%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Nurix Therapeutics Inc (NRIX) Nurix Therapeutics Inc (NRIX) Notizie

Nurix Therapeutics Inc

NRIX
17,64
0,07 (0,40%)
Ultimo aggiornamento: 16:48:08
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/2/202514:42EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
13/2/202522:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202522:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202522:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/2/202513:00GLOBENurix Therapeutics to Participate in the Oppenheimer 35th..
04/2/202502:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202522:33EDGAR2Form 144 - Report of proposed sale of securities
31/1/202501:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202501:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202501:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/1/202522:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/1/202522:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
28/1/202522:03EDGAR2Form 8-K - Current report
28/1/202522:00GLOBENurix Therapeutics Reports Fourth Quarter and Fiscal Year..
22/1/202513:00GLOBENurix Therapeutics Announces Appointment of John Northcott..
13/1/202513:00GLOBENurix Therapeutics Outlines 2025 Goals and Objectives for..
06/1/202513:00GLOBENurix Therapeutics to Participate in the 43rd Annual J.P...
02/1/202523:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202522:20EDGAR2Form 144 - Report of proposed sale of securities
19/12/202413:00GLOBENurix Therapeutics Receives U.S. FDA Fast Track Designation..
10/12/202412:54EDGAR2Form 8-K - Current report
10/12/202400:00GLOBENurix Therapeutics Presents New Positive Data from Phase..
03/12/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/12/202422:36EDGAR2Form 144 - Report of proposed sale of securities
02/12/202413:00GLOBENurix Therapeutics Announces Webcast To Review New Data from..
25/11/202413:00GLOBENurix Therapeutics to Participate in the Piper Sandler 36th..
20/11/202422:00GLOBENurix Therapeutics Receives PRIME Designation from the..
17/11/202416:30GLOBENurix Therapeutics Presents Preclinical Data from Two..
05/11/202415:00GLOBENurix Therapeutics Announces Presentations at the 66th..
04/11/202423:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/11/202422:29EDGAR2Form 144 - Report of proposed sale of securities
01/11/202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202421:50EDGAR2Form 144 - Report of proposed sale of securities
01/11/202421:41EDGAR2Form 144 - Report of proposed sale of securities
31/10/202421:36EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/10/202421:12EDGAR2Form 8-K - Current report
31/10/202421:01EDGAR2Form S-8 - Securities to be offered to employees in employee..
31/10/202412:00GLOBENurix Therapeutics to Participate in Upcoming Investor..
31/10/202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/10/202422:00GLOBENurix Therapeutics Announces Presentations at the 7th Annual..
19/10/202414:00GLOBENurix Therapeutics Presents Positive Results from the..
16/10/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202422:47EDGAR2Form 3 - Initial statement of beneficial ownership of..
16/10/202422:41EDGAR2Form 8-K - Current report
16/10/202422:35GLOBENurix Therapeutics Expands Its Board of Directors with the..
15/10/202415:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/10/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apertura: 17,67 Min: 17,53 Max: 18,02
Chiusura: 17,57

La tua Cronologia

NASDAQ
NRIX
Nurix Therapeutics
LSE
PFO
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci